How Well Is Blood Phenylalanine Controlled in Maternal PKU in Europe? Results from 102 Pregnancies

Alex Pinto1, Kirsten Ahring2, Manuela Ferreira Almeida3,4,5

  • 1Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.

Nutrients
|July 15, 2026
PubMed

Insights

Achieving target blood phenylalanine (Phe) levels before conception in phenylketonuria (PKU) pregnancies is challenging, though metabolic control improves during gestation. Post-pregnancy monitoring for PKU patients is often insufficient.

Area of Science:

  • Metabolic disorders
  • Maternal-fetal medicine
  • Genetics and genomics

Background:

  • High blood phenylalanine (Phe) in phenylketonuria (PKU) during pregnancy causes adverse fetal outcomes (maternal PKU syndrome).
  • Strict metabolic control (Phe levels ≤ 360 µmol/L) is crucial pre-conception and throughout gestation.
  • European study aimed to assess metabolic control in PKU pregnancies.

Purpose of the Study:

  • To evaluate metabolic control in pregnancies affected by phenylketonuria (PKU) across multiple European centers.
  • To analyze blood Phe levels, dietary intake, and monitoring frequency in PKU pregnancies.

Main Methods:

  • Retrospective data collection from 11 European PKU centers (2012-2018).
  • Analysis of blood Phe levels, natural protein intake, protein substitute intake, and maternal weight.
  • Inclusion of 84 patients and 102 pregnancies with varying PKU classifications.

Main Results:

  • Only 27% of pregnancies achieved target Phe levels ≤ 360 µmol/L pre-conception.
  • During pregnancy, 88% of Phe levels were ≤360 µmol/L (mean 229 ± 65 µmol/L).
  • Post-pregnancy monitoring was significantly reduced, with 25% of patients having no recorded levels.

Conclusions:

  • Metabolic control during PKU pregnancies is generally good, but pre-conception control is suboptimal.
  • Minimal post-pregnancy monitoring poses a risk for long-term maternal health.
  • Further research is needed to understand the long-term impact on offspring.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...